Sort
51,593 grants matching “hepatitis”
Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy
$764,128Dale L Greiner · Univ Of Massachusetts Med Sch Worcester · R24 · FY2016 · OD
Pathogenesis of youth onset pre-diabetes and Type 2 diabetes
$764,043Sonia Caprio · Yale University · R01 · FY2023 · DK
Vector-borne pathogen transmission
$764,039Shaden Kamhawi · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$764,020Charles W. Flexner · Johns Hopkins University · R24 · FY2020 · AI
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
$763,999Scott B. Reeder · University Of Wisconsin-Madison · R01 · FY2018 · DK
Role of Wnt-Beta-catenin in liver development and metabolic zonation
$763,804Satdarshan Singh Monga · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DK
Serum Organochlorine Levels and Primary Liver Cancer: A Nested Case-Control Study
$763,744Lawrence Stuart Engel · Sloan-Kettering Inst Can Research · R01 · FY2008 · ES
Computation and Repurposing to identfy antivirals directed against dominant
$763,571Vijay S Pande · Stanford University · U19 · FY2018 · AI
Expansion of Mail-Delivered Harm Reduction Services in the U.S.
$763,511Czarina Navos Behrends · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · DA
HCC Risk Stratification in MAFLD Cirrhosis
$763,507Hashem B El-Serag · Baylor College Of Medicine · P01 · FY2024 · CA
Effect of HBV DNA Methylation and the Mutant 1762T/1764A on Viral Load and HCC
$763,210Kathleen Schwarz · Johns Hopkins University · U01 · FY2011 · DK
Phenylbutyrate therapy for maple syrup urine disease
$763,151Brendan Hl Lee · Baylor College Of Medicine · R01 · FY2011 · DK
A Rhesus Macaque Model of HIV and HBV co-infection
$762,977Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2023 · AI
The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor Growth
$762,851Amato J. Giaccia · Stanford University · R35 · FY2020 · CA
Dietary Fat and HDL Metabolism
$762,788Frank M Sacks · Harvard School Of Public Health · R01 · FY2010 · HL
Clinical & Immunological Study of Treatment Withdrawal in E-Ag Negative Hepatitis B
$762,427Stewart Cooper · California Pacific Med Ctr Res Institute · R01 · FY2021 · DK
Central Mechanisms Regulating Energy Homeostasis, Project 2 of 10
$762,384Joel K Elmquist · Ut Southwestern Medical Center · RL1 · FY2010 · DK
HEPATITIS C: STUDIES OF IMMUNITY AND PATHOGENESIS
$762,360Rockefeller University · U19 · FY2001 · AI
Acute Hepatitis C Infection in Young Injectors
$762,260Kimberly Page · University Of California, San Francisco · R01 · FY2009 · DA
Anti-norovirus protease inhibitors for immunocompromised patients
$762,258Raymond F. Schinazi · Emory University · R01 · FY2024 · AI
A vascularized patient-derived iPSC liver acinus microphysiology system as an innovative precision medicine platform for optimizing clinical trial design for nonalcoholic fatty liver disease
$762,142D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · UH3 · FY2023 · TR
Phase I Trials of Anti-Cancer Agents
$762,134Michael R Grever · Ohio State University · U01 · FY2010 · CA
Long-acting Antiviral Treatment for HBV
$762,072Rodney J.y. Ho · University Of Washington · R01 · FY2024 · AI
The Impact of HCV Infection on Bone Turnover, Density, and Strength
$762,061Todd T Brown · Johns Hopkins University · R01 · FY2017 · AI
The Staying Safe Intervention: Preventing HCV among Young Opioid Injectors
$761,598Pedro Mateu-Gelabert · National Development And Research Institutes, Inc. · R01 · FY2016 · DA